Chronic exposure to cannabidiol induces reproductive toxicity in male Swiss mice

Carvalho, Renata Karine de; Santos, Mateus Pereira dos; Souza, Maingredy Rodrigues; Rocha, Thiago Lopes; Guimarães, Francisco Silveira; Anselmo-Franci, Janete Aparecida; Mazaro-Costa, Renata

doi:10.1002/jat.3731

Cited by 11 publications

(6 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The impairment of spermatogenesis following exposure to doses ≥ 15 mg/kg bw per day CBD during at least one cycle of spermatogenesis in sexually mature murine and simian models was confirmed through associations with decreased sperm quality, including decreases in epididymal sperm counts and increases in sperm morphological abnormalities (Rosenkrantz et al., 1981; Patra and Wadsworth, 1991; Carvalho et al., 2018a).…”

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 95%

“…In oral in vivo toxicity studies in sexually mature murine and simian models, CBD displayed potential to affect gonadotropin [including luteinising hormone (LH) and follicle‐stimulating hormone (FSH)] and sex hormone (including, testosterone, oestradiol and progesterone) levels, in both males and females, at doses starting from 30 mg/kg per day (Rosenkrantz and Esber, 1980; Carvalho et al., 2018a, 2018b). A series of single dose (50 mg/kg bw CBD) gestational and perinatal exposure studies in mice also produced these changes at adult age in males (Dalterio et al., 1984a,b, 1986; Dalterio and deRooij, 1986).…”

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 99%

See 1 more Smart Citation

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Turck¹,

Bohn²,

Castenmiller³

et al. 2022

EFS2

View full text Add to dashboard Cite

The European Commission has determined that cannabidiol (CBD) can be considered as a novel food (NF), and currently, 19 applications are under assessment at EFSA. While assessing these, it has become clear that there are knowledge gaps that need to be addressed before a conclusion on the safety of CBD can be reached. Consequently, EFSA has issued this statement, summarising the state of knowledge on the safety of CBD consumption and highlighting areas where more data are needed. Literature searches for both animal and human studies have been conducted to identify safety concerns. Many human studies have been carried out with Epidyolex ® , a CBD drug authorised to treat refractory epilepsies. In the context of medical conditions, adverse effects are tolerated if the benefit outweighs the adverse effect. This is, however, not acceptable when considering CBD as a NF. Furthermore, most of the human data referred to in the CBD applications investigated the efficacy of Epidyolex (or CBD) at therapeutic doses. No NOAEL could be identified from these studies. Given the complexity and importance of CBD receptors and pathways, interactions need to be taken into account when considering CBD as a NF. The effects on drug metabolism need to be clarified. Toxicokinetics in different matrices, the half‐life and accumulation need to be examined. The effect of CBD on liver, gastrointestinal tract, endocrine system, nervous system and on psychological function needs to be clarified. Studies in animals show significant reproductive toxicity, and the extent to which this occurs in humans generally and in women of child‐bearing age specifically needs to be assessed. Considering the significant uncertainties and data gaps, the Panel concludes that the safety of CBD as a NF cannot currently be established.

show abstract

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 95%

Section: Limitations and Uncertainties In Scientific Literaturementioning

confidence: 99%

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Turck¹,

Bohn²,

Castenmiller³

et al. 2022

EFS2

View full text Add to dashboard Cite

show abstract

“…According to traditional protocols, drug toxicity is first tested in pre-clinical animal models. Pre-clinical studies, carried out on animal models, reported acute and chronic adverse effects of CBD on different organs and systems ( Table A2 ) [ 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 ]. There are several highly recommended comprehensive reviews, which critically analyzed the CBD safety and toxicity experiments carried out in animal pre-clinical and human clinical trials [ 53 , 123 , 124 , 125 , 126 , 127 ].…”

Section: Cbd Tolerability Toxicity and Adverse Effectsmentioning

confidence: 99%

Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

et al. 2022

View full text Add to dashboard Cite

Cannabidiol (CBD), a major non-psychotropic component of cannabis, is receiving growing attention as a potential anticancer agent. CBD suppresses the development of cancer in both in vitro (cancer cell culture) and in vivo (xenografts in immunodeficient mice) models. For critical evaluation of the advances of CBD on its path from laboratory research to practical application, in this review, we wish to call the attention of scientists and clinicians to the following issues: (a) the biological effects of CBD in cancer and healthy cells; (b) the anticancer effects of CBD in animal models and clinical case reports; (c) CBD’s interaction with conventional anticancer drugs; (d) CBD’s potential in palliative care for cancer patients; (e) CBD’s tolerability and reported side effects; (f) CBD delivery for anticancer treatment.

show abstract

“… In males, because of its increased toxicity, Cannabis sativa is not commonly utilized as a natural infertility inducer [91].…”

Section: Cannabinoidsmentioning

confidence: 99%

Impending Contraceptives That Might Be a Positive Methodology Towards the Male Contraception

et al. 2022

View full text Add to dashboard Cite

The total population has been developing dramatically; be that as it may, right now, the decisions for male contraception are restricted. This study investigates continuous explores of male contraceptives. This study article is primarily based on the thought of contraception that must be needed toward the increasing population and giving the ideal strategy to control the fertility of humans and animals. This review featured the recent oral male contraceptives that may be revolutionary products in our world as means of contraception. The audit article considers that these contraceptives are customarily utilized for their spermicidal activities and their fundamental hormones of the awkwardness for fertility and the mechanism of activity of the impact of the antifertility of contraceptives. The present study offers up-to-date data gathered on the contraceptives used for anti-fertility activity in males. The goal of this study is to spotlight the work on the anti-fertility effect of contraceptives. Therefore these products can provide options and lowering fertility would be higher than different contraceptives. This article can also assist investigators in developing the newer contraceptive preparation for anti-fertility activity in males. The innovations in this field are important to focus on current, more intense medication having a less detrimental effect on the body function and that can be administrable on its entity, less expensive, and quite reversible.

show abstract

Chronic exposure to cannabidiol induces reproductive toxicity in male Swiss mice

Cited by 11 publications

References 1 publication

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Statement on safety of cannabidiol as a novel food: data gaps and uncertainties

Cannabidiol on the Path from the Lab to the Cancer Patient: Opportunities and Challenges

Impending Contraceptives That Might Be a Positive Methodology Towards the Male Contraception

Contact Info

Product

Resources

About